Reduced in vitro Production of Interferon-Gamma, Interleukin-4 and Interleukin-12 and Increased Production of Interleukin-6, Interleukin-10 and Tumour Necrosis Factor-Alpha in Systemic Lupus Erythematosus. Weak Correlations of Cytokine Production with Disease Activity

References

• Isenberg D. A., Dudeney C, Williams W., Todd-Popropek A., Stollar B. D. Disease activity in systemic lupus erythematosus related to a range of antibodies binding DNA and synthetic polynucleotides. Ann. Rheum. Dis 1988; 47: 717–724
   PubMedGoogle Scholar
• Steinberg A. D., Gourley M. F., Klinman D. M., Tsokos G. C., Scott D. E., Kreig A. M. Systemic lupus erythematosus. Ann. Intern. Med 1991; 115: 548–559
   PubMed Web of Science ®Google Scholar
• Ogawa N., Itoh M., Goto Y. Abnormal production of B-cell growth factor in patients with systemic lupus erythematosus. Clin. Exp. Immunol 1992; 89: 26–31
   PubMedGoogle Scholar
• Cuadrado M. J., Marubayashi M, Ortega C, Fernandez-Areas N., Garcia-Cozar F., Pena J., et al. Relationship of 1L2, 1L2R (CD25), soluble IL2-R and IL4 with disease activity in SLE patients. Lupus 1993; 2: 257–260
   PubMedGoogle Scholar
• Linker-Israeli M., Deans R. J., Wallace D. J., Prchn J., Ozeri-Chen T., Klinenberg J. R., et al. Elevated levels of endogenous IL6 in systemic lupus erythematosus. A putative role in pathogenesis. J. Immunol 1991; 147: 117–123
   PubMed Web of Science ®Google Scholar
• Spronk P., Ter Borg E., Limburg P., Kallcnberg C. Plasma concentrations of 1L6 in systemic lupus erythematosus: an indication of disease activity. Clin. Exp. Immunol 1992; 90: 106–110
   PubMed Web of Science ®Google Scholar
• Houssiau F. A., Lefebvre C, Van den Berghe M., Lambert M., Devogelaer J. P., Goldman M., et al. Serum interleukin 10 tilers in systemic lupus erythematosus reflect disease activity. Lupus 1995; 4: 393–395
   PubMed Web of Science ®Google Scholar
• Studnicka-Benke A., Steiner G., Pctera P., Smolen J. S. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br. J. Rheumatol 1996; 35: 1067–1074
   PubMedGoogle Scholar
• Mongan A. E., Ramdahin S., Warrington R. J. Interleukin-10 response abnormalities in systemic lupus erythematosus. Scancl. J. Immunol 1997; 46: 406–412
   PubMed Web of Science ®Google Scholar
• al-Janadi M., al-Balla S., al-Dalaan A., Raziuddin S. Cytokine profiles in systemic lupus erythematosus, rheumatoid arthritis and other rheumatic diseases. J. Clin. Immunol 1993; 13: 58–67
   PubMed Web of Science ®Google Scholar
• Alcocer-Varela J., Llorente L., Alarcon-Segovia D. Immunoregulalory circuits and potential treatment of connective tissue diseases. Int. Arch. Allergy Immunol 1996; 111: 348–354
   PubMedGoogle Scholar
• Richaud-Patin Y., Alcocer-Varela J., Llorente L. High levels of TH2 cytokine gene expression in systemic lupus erythematosus. Rev. Invest. Clin 1995; 47: 267–272
   PubMedGoogle Scholar
• Liu T. F., Jones B. M. Impaired production of IL12 in systemic lupus erythematosus. I. Excessive production of ILK) suppresses production of ILI2 by monocytes. Cytokine 1998; 10: 140–147
   PubMedGoogle Scholar
• Liu T. F., Jones B. M. Impaired production of IL12 in systemic lupus erythematosus. II. 1L12 production is correlated negatively with serum 1L10, positively with serum IFN7 and negatively with disease activity in SLE. Cytokine 1998; 10: 148–153
   PubMedGoogle Scholar
• Hagiwara E., Gourley M. F., Lee S., Klinman D. M. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin 10: interferon-γ-secreting cells in the peripheral blood. Arlh. Rheum 1996; 39: 379–385
   PubMed Web of Science ®Google Scholar
• Czerkinsky C. C., Nilsson L. A., Nygren H., Ouchterlony O., Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J. Immunol. Methods 1983; 65: 109–121
   PubMed Web of Science ®Google Scholar
• Sedgwick J. D., Holt P. G. A solid-phase immuno-enzymatic technique for the enumeration of specific antibody-secreting cells. J Immunol. Methods 1983; 57: 301–309
   PubMed Web of Science ®Google Scholar
• Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., et al. The 1982 revision criteria for the classification of systemic lupus erythematosus. Arlh. Rheum 1982; 25: 1271–1277
   PubMed Web of Science ®Google Scholar
• Bombardier C, Gladman D. D., Urowitz M. B., Caron D., Chang C. H. Derivation of the SLEDAI. A disease activity index for lupus patients. Arlh. Rheum 1992; 35: 630–640
   PubMed Web of Science ®Google Scholar
• Kobayashi M., Fitz L., Ryan M., Hewick R. M., Clark S. C., Chan S., et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J. Exp. Med 1989; 170: 827–845
   PubMed Web of Science ®Google Scholar
• D'Andrea A., Rengaraju M., Valiante N. M., Chehimi J., Kubin M., Aste-Amezaga M., et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp. Med 1992; 176: 1387–1398
   PubMed Web of Science ®Google Scholar
• Maruo S., Oh-Hora M., Aim H. I., Ono S., Wysocka M., Kaneko Y., et al. B cells regulate CD40 ligand-induced IL-12 production in antigen-presenting cells (APC) during T cell/APC interactions. J. Immunol 1997; 158: 120–126
   PubMed Web of Science ®Google Scholar
• Mosmann T. R., Cherwinski H., Bond M. W., Giedlin M. A., Coffman R. L. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol 1986; 136: 2348–2357
   PubMed Web of Science ®Google Scholar
• Romagnani S. The Thl/Th2 paradigm. Immunol. Today 1997; 18: 263–266
   PubMedGoogle Scholar
• Seder R. A., Paul W. E. Acquisition of lymphokine-producing phenotype by CD4f cells. Ann. Rev. Immunol 1994; 12: 635–673
   PubMed Web of Science ®Google Scholar
• Kitani A., Hara M., Hirose T., Harigai M., Suzuki K., Kawakami M., et al. Autostimulatory effects of IL6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and 1L-6R expression. Clin. Exp. Immunol 1992; 88: 75–83
   PubMed Web of Science ®Google Scholar
• Llorente L., Richaud-Patin Y., Wijdenes J., Alcocer-Varela J., Maillot M. C., Durand-Gassclin I., et al. Spontaneous production of interleukin-10 by B-lymphocytes and monocytes in systemic lupus erythematosus. Eur. Cytokine Network 1993; 4: 421–427
   PubMed Web of Science ®Google Scholar
• Llorente L., Zou W., Levy Y., Richaud-Patin Y., Wijdenes J., Alcocer-Varela J., et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J. Exp. Med 1995; 181: 839–844
   PubMed Web of Science ®Google Scholar
• Berger S., Chandra R., Ballo H., Hildenbrand R., Stutte H. J. Immune complexes are potent inhibitors of interleukin-12 secretion by human monocytes. Eur. J. Immunol 1997; 27: 2994–3000
   PubMed Web of Science ®Google Scholar
• Moreland L. W., Baumgartner S. W., Scruff M. H, Tindall E. A, Fleischmann R. M., Weaver A. L., et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Eng. J. Med 1997; 337: 141–147
   PubMed Web of Science ®Google Scholar
• Liu T. F, Jones B. M, Wong R. W.S., Srivastava G. Impaired production of IL-12 in systemic lupus erythematosus. III. Deficient IL-12 p40 gene expression and cross-regulation of IL-12, IL-10 and IFNγ gene expression. Cytokine 1999; 11, in press
   Google Scholar
• Jones B. M., Kwok C. C.H., Kung A. W.C. Effect of radioactive iodine therapy on cytokine production in Graves disease: transient increases in interleukin-4 (IL-4), IL-6, IL-10 and tumour necrosis factor-α, with longer term increases in interferon-γ production. J. Clin. Endocrinol. Melahol 1999; 84, in press
   Google Scholar